Abstract
Several cost-of-illness (COI) studies related to diabetes mellitus have been performed over the last three decades. This review examines the results of these COI studies, identifies the strengths and limitations of the various methods utilised, and suggests future research that will help determine the economic burden of diabetes more accurately.
Diabetes imposes a large economic burden on society. The economic cost of diabetes is estimated to be as much as $US100 billion per year in the US alone (1997 values). This estimated cost has increased notably over time, primarily due to price inflation and the increasing prevalence of diabetes. Differing methodologies have significantly influenced the cost estimates and made comparisons between COI studies problematic. For example, early reports tended to rely exclusively on data where diabetes was listed as the primary diagnosis or reason for healthcare use. To better capture the costs associated with diabetes-related complications, later studies have included costs related to diabetes as a secondary or tertiary diagnosis using the attributable risk methodology. Given the types of long-term complications that are associated with diabetes, attempts at capturing these secondary costs are appropriate. However, estimates of attributable risk can be limited by the epidemiological data currently available.
The tremendous economic burden of diabetes makes the disease an important clinical and public health problem. In order to formulate an effective response to this problem, it is important to track future economic trends as healthcare delivery, morbidity and mortality patterns evolve. Future research efforts should focus on refining methods to estimate costs, improving the interpretation of study findings, and facilitating comparisons between studies.
Similar content being viewed by others
References
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414–31
Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050. Diabetes Care 2001; 24: 1936–40
Alberti KGMM, DeFronzo RA, Zimmet P, editors. International textbook of diabetes mellitus. New York: John Wiley & Sons, 1995
Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16: 642–52
Rubin RJ, Altman WM, Mendelson DN. Health care expenses for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78: 809A-F
American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21: 296–309
Rice DP. Cost-of-illness studies: fact or fiction? Lancet 1994; 344: 1519–20
Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy 1987; 8: 317–23
Behrens C, Henke K-D. Cost of illness studies: no aid to decision making?: reply to Shiell. Health Policy 1989; 10: 137–41
Hodgson TA. Cost of illness studies: no aid to decision making?: comments on the second opinion by Shiell, et al. Health Policy 1989; 11: 57–60
Wiseman V, Money G. Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998; 43: 243–51
Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US costof-illness studies in healthcare decision making. Pharmacoeconomics 2001; 19 (2): 207–13
Fein R. Economics of public health. New York: Basic Books, 1958
Mushkin SJ, Collings F. Economic costs of disease and injury. Public Health Reports 1959; 74: 795–809
Weisbrod BA. Economics of public health. Philadelphia: University of Pennsylvania Press, 1961
Rice DP, Cooper BS. The economic value of human life. Am J Public Health 1967; 57: 1954–66
Rice DP. Estimating the cost of illness: health economics series No. 6, PHS No. 947–6. Washington, DC: US Government Printing Office, 1966
Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39: 21–36
Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev 1985; 7: 61–80
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Millbank Mem Fund Q 1982; 60: 429–62
Scitovsky AA. Estimating the direct cost of illness. Millbank Mem Fund Q 1982; 60: 462–91
Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life?: a response to the recommendations of the Washington Panel. Health Econ 1997; 6: 253–9
Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ 1997; 6: 505–10
Lubeck DP, Yelin EH. A question of value: measuring the impact of chronic disease. Millbank Mem Fund Q 1988; 66: 445–64
Schelling TC. The life you save may be your own: in problems in public expenditure analysis. Washington, DC: The Brookings Institute, 1968
Mishan EJ. Evaluation of life and limb: a theoretical approach. J Polit Econ 1971; 79: 687–705
Gafni A. Willingness-to-pay as a measure of benefits: relevant questions in the context of public decision-making about health care programs. Med Care 1991; 29: 1246–52
Koopmanschap MA, Ineveld BMV. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 9: 1005–10
Drummond MF, O’Brien B, Greg GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
Pagano E, Brunetti M, Tediosi F, et al. Costs of diabetes; a methodological analysis of the literature. Pharmacoeconomics 1999; 15 (6): 583–95
Harris MI, Entmacher PS. Mortality from diabetes: in the National Diabetes Data Group Diabetes in America, diabetes data compiled 1984. Washington, DC: US Government Printing Office, 1985 Aug. NIH Pub. No. 85–1468
Sinnock P. Hospital utilization for diabetes: in the National Diabetes Data Group Diabetes in America, diabetes data compiled 1984. Washington, DC: US Government Printing Office, 1985 Aug. NIH Pub. No. 85–1468
Palumbo PJ, Elveback LR. Diabetes mellitus: incidence, prevalence, survivorship, and causes of death. Diabetes 1976; 25: 566–73
Mayfield JA, Deb P, Whitecotton L. Work disability and diabetes. Diabetes Care 1999; 22 (7): 1105–9
Entmacher PS. Report of economic impact of diabetes. Washington, DC: US Government Printing Office, 1976. NIH Publication No. 76–1022, vol 3, part 2
Entmacher PS, Sinnock P, Bostic E, et al. The economic impact of diabetes: in the National Diabetes Data Group Diabetes in America, diabetes data compiled 1984. Washington, DC: US Government Printing Office, 1985 Aug. NIH Pub. No. 85–1468
Werner JL, Tokuhata GK. Diabetes mellitus: its annual cost in Pennsylvania and the United States, 1975. NTIS order no. HRP-0006964. Harrisburg (PA): Bureau of Health Research, Pennsylvania Department of Health, 1975 Nov
Taylor AK. Medical expenditures and insurance coverage for people with diabetes: estimates from the National Medical Care Expenditure Survey. Diabetes Care 1987; 10: 87–94
Jönsson B. Diabetes: the cost of illness and the cost of control. Acta Med Scand Suppl 1983; 671: 19–27
Platt WG, Sudover SG. The social and economic costs of diabetes: an estimate for 1979. In: Elkhart IN, editor. Home health care group. Elkhart (IN): Ames Division, Miles Laboratories Inc, 1983
Miller LV. Socioeconomic impact of diabetes mellitus. In Brodoff ON, Bleicher SJ, editors. Diabetes mellitus and obesity. Baltimore (MD): Williams & Wilkins, 1982
Smeeding TM, Booton LA. Measuring and valuing the economic benefits of diabetes control. In: Proceedings of the Nineteenth National Public Health Conference on Records and Statistics. DHHS pub no. (PHS) 81–1214. Hyattsville (MD): DHHS, Public Health Service, National Center for Health Statistics, 1983 Dec
Lipsett L. The economic cost of diabetes. In: Laron Z, Galatzer A, editors. Pediatric and adolescent endocrinology, volume II: recent progress in medico-social problems in juvenile diabetics. Basel: Karger, 1983
Carter Center. Closing the Gap: the problem of diabetes mellitus in the United States. Diabetes Care 1985; 8: 391–406
Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabet Med 1989; 6: 164–70
Huse DM, Oster G, Killen AR, et al. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989; 262: 2708–13
Pracon Inc. Direct and indirect costs of diabetes in the United States in 1987. Alexandria (VA): American Diabetes Association, 1988
Weinberger M, Cowper PA, Kirkman MS, et al. Economic impact of diabetes mellitus in the elderly. Clin Geriatr Med 1990; 6: 959–70
Roesler J, Bishop D, Walseth J. Economic cost of diabetes mellitus Minnesota, 1988. MMWR Morb Mortal Wkly Rep 1991; 40: 229–31
Kegler MC, Lengerich EJ, Norman M, et al. The burden of diabetes in North Carolina. N C Med J 1995; 56: 141–4
Warner DC, McCandless RR, De Nino LA, et al. Cost of diabetes in Texas, 1992. Diabetes Care 1996; 19: 1416–9
American Diabetes Association. Direct and indirect costs of diabetes in the United States in 1992. Alexandria (VA): American Diabetes Association, 1993
Thom TJ. Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo 1996; 10: 255–60
Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998; 244: 461–8
National Institutes of Health. Disease-specific estimates of direct and indirect costs of illness and NIH support. Bethesda (MD): National Institutes of Health, 1995 Nov
Hodgson TA, Cohen AJ. Medical care expenditures for diabetes, its chronic complications, and its comorbidities. Prev Med 1999; 29: 173–86
Selby JV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997; 20: 1396–402
Brown BJ, Glauber HS, Nichols AG, et al. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 1999; 22: 1116–24
Jacobs P, Blanchard JF, James RC, et al. Excess costs of diabetes in aboriginal population of Manitoba, Canada. Can J Public Health 2000; 91: 298–301
Jonsson PM, Marke L, Nystrom L, et al. Excess costs of medical care 1 and 8 years after diagnosis of diabetes: estimates from young and middle aged incidence cohort in Sweden. Diabetes Res Clin Pract 2000; 50: 35–47
Policy Analysis Inc. Evaluation of cost of illness ascertainment methodology: Part II. applications of methodology to ascertain lifetime economic costs of illness in an incidence cohort: final report to the National Center for Health Statistics. DHHS Contract No. 233–79-2048. Ann Arbor (MI): Policy Analysis Inc., 1981 Dec
Hart WM, Espinosa C, Rovira J. A simulation model of the cost of the incidence of IDDM in Spain. Diabetologia 1997; 40: 311–8
Stern Z, Levy R. The direct cost of type 1 diabetes mellitus in Israel. Diabet Med 1994; 11: 528–33
Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 1995; 12: 1068–76
Acknowledgements
This research was supported by a contract from the Division of Diabetes Translation, Centers for Disease Control & Prevention, Atlanta, GA. There are no conflicts of interest for the authors as it applies to the content of the manuscript. The authors wish to thank the members of the Economics of Diabetes Project Panel for their comments on this work: Partha Deb, PhD.; Cameron Donaldson, PhD.; Nancy Ray Fox, PhD.; Joel W. Greer, PhD.; Thomas Hodgson, PhD.; Willard G. Manning, Jr.; PhD., Dorothy P. Rice, PhD.; Robert J. Rubin, MD; and Steven M. Teustch, MD, MPH.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ettaro, L., Songer, T.J., Zhang, P. et al. Cost-of-Illness Studies in Diabetes Mellitus. PharmacoEconomics 22, 149–164 (2004). https://doi.org/10.2165/00019053-200422030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200422030-00002